drugset
drugset / Trial / NCT05036434

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

NCT05036434 ↗

Phase 2 Active not recruiting 30 enrolled National Cancer Center, Korea MSD Korea Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

* Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy * Trial Type : Single arm, prospective trial * Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) * Treatment Groups : Single arm * Number of trial participants : 30

Timeline

Start
2021-11-15
Primary completion
2027-02-28
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 20 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

adrenal cortex carcinoma